SourceBio International has agreed to purchase the entire issued capital of LDPath, a London-based leader in digital pathology testing services.
Source provides ISO15189-certified and UKAS-accredited diagnostic testing and cellular pathology services to the NHS and other healthcare providers offering tailored solutions within its histopathology services, from wets to report, dependent on needs.
LDPath has built its own intellectual property to pioneer the creation of a digital pathology platform, which is already being successfully rolled out and adopted in the marketplace. Its technology-enabled offering has been adopted within private healthcare providers and NHS trusts and is complementary to Source’s strategic direction and its own digital approach.
The combined Source LDPath pathology workflow, with its market-leading digital and AI pathology services and link to further in-house precision medicine tests, provides a complete patient journey from first consultant contact to diagnosis. This enhanced capacity is a strategic move to accelerate the growth and strength of Source’s leadership in cellular pathology and will further enable its commitment to support the sector globally.